These findings demonstrated that the neoAg-mRNA-LNP vaccine induces a more robust population of tumor-reactive, neoAg-specific CD8+ T cells than the neoAg-DC vaccine, resulting in a stronger antitumor immune response. This evidence concerns the gene CD8A and neoplasm.